{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:32:38Z","timestamp":1772119958199,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Department of Science and Technology of Guizhou Province","award":["QKHZC[2021]YB450"],"award-info":[{"award-number":["QKHZC[2021]YB450"]}]},{"name":"the Department of Science and Technology of Guizhou Province","award":["QKHZC[2022]YB189"],"award-info":[{"award-number":["QKHZC[2022]YB189"]}]},{"name":"the Guizhou Provincial Committee Organization Department","award":["QKHPTRC-GCC[2022]034-1"],"award-info":[{"award-number":["QKHPTRC-GCC[2022]034-1"]}]},{"name":"the Science and Social Development of Anshun City","award":["ASKS(2021)19"],"award-info":[{"award-number":["ASKS(2021)19"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-024-02324-6","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T04:02:40Z","timestamp":1712808160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel \u03b1,\u03b2-unsaturated ketone inhibits leukemia cell growth as PARP1 inhibitor"],"prefix":"10.1007","volume":"41","author":[{"given":"Weijia","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiping","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baofei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"issue":"3","key":"2324_CR1","first-page":"38","volume":"103","author":"A Pelcovits","year":"2020","unstructured":"Pelcovits A, Niroula R. Acute myeloid leukemia: a review. R I Med J. 2020;103(3):38\u201340.","journal-title":"R I Med J"},{"issue":"1","key":"2324_CR2","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12906-017-1867-0","volume":"17","author":"FAA Omer","year":"2017","unstructured":"Omer FAA, Hashim NM, Ibrahim MY, et al. Beta-mangostin demonstrates apoptogenesis in murine leukaemia (WEHI-3) cells in vitro and in vivo. BMC Complement Altern Med. 2017;17(1):366.","journal-title":"BMC Complement Altern Med"},{"key":"2324_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40199-015-0139-0","volume":"24","author":"S Norouzi","year":"2016","unstructured":"Norouzi S, Norouzi M, Amini M, et al. Two COX-2 inhibitors induce apoptosis in human erythroleukemia K562cells by modulating NF-\u03baB and FHC pathways. Daru. 2016;24:1.","journal-title":"Daru"},{"issue":"1","key":"2324_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"2324_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2017.01.007","volume":"50","author":"H Cao","year":"2017","unstructured":"Cao H, Xu Y, de Necochea-Campion R, et al. Application of vitamin D and vitamin D analogs in acute myelogenous leukemia. Exp Hematol. 2017;50:1\u201312.","journal-title":"Exp Hematol"},{"issue":"1","key":"2324_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1517\/14656566.2015.981527","volume":"16","author":"CD DiNardo","year":"2015","unstructured":"DiNardo CD, Cortes JE. New treatment for acute myelogenous leukemia. Expert Opin Pharmacother. 2015;16(1):95\u2013106.","journal-title":"Expert Opin Pharmacother"},{"key":"2324_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2021.106029","volume":"137","author":"M Floren","year":"2021","unstructured":"Floren M, Gillette JM. Acute myeloid leukemia: therapy resistance and a potential role for tetraspanin membrane scaffolds. Int J Biochem Cell Biol. 2021;137: 106029.","journal-title":"Int J Biochem Cell Biol"},{"issue":"6","key":"2324_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3322\/canjclin.44.6.326","volume":"44","author":"SM Devine","year":"1994","unstructured":"Devine SM, Larson RA. Acute leukemia in adults: recent developments in diagnosis and treatment. CA Cancer J Clin. 1994;44(6):326\u201352.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"2324_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s12098-015-1695-5","volume":"82","author":"R Seth","year":"2015","unstructured":"Seth R, Singh A. Leukemias in Children. Indian J Pediatr. 2015;82(9):817\u201324.","journal-title":"Indian J Pediatr"},{"issue":"13","key":"2324_CR10","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1080\/10428194.2020.1802450","volume":"61","author":"CK Major","year":"2020","unstructured":"Major CK, Kantarjian H, Sasaki K, et al. Survivorship in AML: a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma. 2020;61(13):3120\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2324_CR11","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bjh.17746","volume":"196","author":"S Kayser","year":"2022","unstructured":"Kayser S, Levis MJ. Updates on targeted therapies for acute myeloid leukaemia. Br J Haematol. 2022;196(2):316\u201328.","journal-title":"Br J Haematol"},{"issue":"9","key":"2324_CR12","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.3390\/curroncol29090491","volume":"29","author":"RJ Stubbins","year":"2022","unstructured":"Stubbins RJ, Francis A, Kuchenbauer F, et al. Management of Acute myeloid leukemia: a review for general practitioners in oncology. Curr Oncol. 2022;29(9):6245\u201359.","journal-title":"Curr Oncol"},{"issue":"1","key":"2324_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","volume":"127","author":"D Grimwade","year":"2016","unstructured":"Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29\u201341.","journal-title":"Blood"},{"issue":"6","key":"2324_CR14","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.hoc.2017.08.006","volume":"31","author":"H Rose-Inman","year":"2017","unstructured":"Rose-Inman H, Kuehl D. Acute leukemia. Hematol Oncol Clin North Am. 2017;31(6):1011\u201328.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10","key":"2324_CR15","first-page":"749","volume":"18","author":"HM Ding","year":"2020","unstructured":"Ding HM, Chen XJ, Chen HM, et al. Effect of Sargassum fusiforme polysaccharide on apoptosis and its possible mechanism in human erythroleukemia cells. Chin J Nat Med. 2020;18(10):749\u201359.","journal-title":"Chin J Nat Med"},{"issue":"9","key":"2324_CR16","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/ijc.33908","volume":"150","author":"S Ganesan","year":"2022","unstructured":"Ganesan S, Mathews V, Vyas N. Microenvironment and drug resistance in acute myeloid leukemia: do we know enough? Int J Cancer. 2022;150(9):1401\u201311.","journal-title":"Int J Cancer"},{"issue":"1","key":"2324_CR17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s13046-018-0976-z","volume":"37","author":"X Huang","year":"2018","unstructured":"Huang X, Xiao F, Li Y, et al. Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia. J Exp Clin Cancer Res. 2018;37(1):310.","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"2324_CR18","first-page":"1688","volume":"32","author":"FC Weiming Huang","year":"2020","unstructured":"Weiming Huang FC, Bian Yuting, Zhang Ruizeng, et al. Chemical constituents from Chloranthus multistachys and their anti-inflammatory activity. Nat Product Res Dev. 2020;32(10):1688\u201397.","journal-title":"Nat Product Res Dev"},{"issue":"04","key":"2324_CR19","first-page":"459","volume":"19","author":"X Yang","year":"2017","unstructured":"Yang X. Bioactive material basis of medicinal plants in genus Chloranthus. Mod Chin Med. 2017;19(04):459\u201395.","journal-title":"Mod Chin Med"},{"issue":"4","key":"2324_CR20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/10286020.2022.2092474","volume":"25","author":"JB Xu","year":"2023","unstructured":"Xu JB, Yu J, Zhang WQ, et al. Constituents from Chloranthus multistachys and their cytotoxic activities against various human cancer cell lines. J Asian Nat Prod Res. 2023;25(4):330\u201341.","journal-title":"J Asian Nat Prod Res"},{"key":"2324_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.564601","volume":"8","author":"M Rose","year":"2020","unstructured":"Rose M, Burgess JT, O\u2019Byrne K, et al. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8: 564601.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"2324_CR22","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.biocel.2004.09.011","volume":"37","author":"ML Meyer-Ficca","year":"2005","unstructured":"Meyer-Ficca ML, Meyer RG, Jacobson EL, et al. Poly(ADP-ribose) polymerases: managing genome stability. Int J Biochem Cell Biol. 2005;37(5):920\u20136.","journal-title":"Int J Biochem Cell Biol"},{"issue":"24","key":"2324_CR23","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.3390\/cancers13246385","volume":"13","author":"CM Csizmar","year":"2021","unstructured":"Csizmar CM, Saliba AN, Swisher EM, et al. PARP inhibitors and myeloid neoplasms: a double-edged sword. Cancers (Basel). 2021;13(24):6385.","journal-title":"Cancers (Basel)"},{"issue":"22","key":"2324_CR24","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1182\/bloodadvances.2021004638","volume":"5","author":"CN Kontandreopoulou","year":"2021","unstructured":"Kontandreopoulou CN, Diamantopoulos PT, Tiblalexi D, et al. PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2021;5(22):4794\u2013805.","journal-title":"Blood Adv"},{"issue":"1","key":"2324_CR25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s12885-020-06903-4","volume":"20","author":"P Gil-Kulik","year":"2020","unstructured":"Gil-Kulik P, Dudzi\u0144ska E, Radzikowska-B\u00fcchner E, et al. Different regulation of PARP1, PARP2, PARP3 and TRPM2 genes expression in acute myeloid leukemia cells. BMC Cancer. 2020;20(1):435.","journal-title":"BMC Cancer"},{"issue":"1","key":"2324_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-022-01228-0","volume":"15","author":"A Padella","year":"2022","unstructured":"Padella A, Ror\u00e0 Ghelli Luserna Di, A, Marconi G, et al. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies. J Hematol Oncol. 2022;15(1):10.","journal-title":"J Hematol Oncol."},{"issue":"2","key":"2324_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1139","volume":"2","author":"T Nemkov","year":"2019","unstructured":"Nemkov T, D\u2019Alessandro A, Reisz JA. Metabolic underpinnings of leukemia pathology and treatment. Cancer Rep (Hoboken). 2019;2(2): e1139.","journal-title":"Cancer Rep (Hoboken)"},{"issue":"5","key":"2324_CR28","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11864-023-01066-3","volume":"24","author":"RP Gale","year":"2023","unstructured":"Gale RP. Can Immune therapy cure acute myeloid leukemia? Curr Treat Options Oncol. 2023;24(5):381\u20136.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"2324_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12094-019-02132-9","volume":"22","author":"M Maleknia","year":"2020","unstructured":"Maleknia M, Valizadeh A, Pezeshki SMS, Saki N. Immunomodulation in leukemia: cellular aspects of anti-leukemic properties. Clin Transl Oncol. 2020;22(1):1\u201310.","journal-title":"Clin Transl Oncol"},{"issue":"11","key":"2324_CR30","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1080\/10428194.2018.1434886","volume":"59","author":"C Karantanou","year":"2018","unstructured":"Karantanou C, Godavarthy PS, Krause DS. Targeting the bone marrow microenvironment in acute leukemia. Leuk Lymphoma. 2018;59(11):2535\u201345.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2324_CR31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.18632\/aging.100934","volume":"8","author":"G Pistritto","year":"2016","unstructured":"Pistritto G, Trisciuoglio D, Ceci C, et al. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 2016;8(4):603\u201319.","journal-title":"Aging (Albany NY)"},{"issue":"1\u20132","key":"2324_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","volume":"28","author":"D Kaloni","year":"2023","unstructured":"Kaloni D, Diepstraten ST, Strasser A, et al. BCL-2 protein family: attractive targets for cancer therapy. Apoptosis. 2023;28(1\u20132):20\u201338.","journal-title":"Apoptosis"},{"issue":"6","key":"2324_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.251","volume":"5","author":"N Bah","year":"2014","unstructured":"Bah N, Maillet L, Ryan J, et al. Bcl-xL controls a switch between cell death modes during mitotic arrest. Cell Death Dis. 2014;5(6): e1291.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2324_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/13510002.2017.1416773","volume":"23","author":"K Beyfuss","year":"2018","unstructured":"Beyfuss K, Hood DA. A systematic review of p53 regulation of oxidative stress in skeletal muscle. Redox Rep. 2018;23(1):100\u201317.","journal-title":"Redox Rep"},{"issue":"1","key":"2324_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-021-01061-x","volume":"14","author":"D Teyssonneau","year":"2021","unstructured":"Teyssonneau D, Margot H, Cabart M, et al. Prostate cancer and PARP inhibitors: progress and challenges. J Hematol Oncol. 2021;14(1):51.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2324_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","volume":"16","author":"L Cortesi","year":"2021","unstructured":"Cortesi L, Rugo HS, Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 2021;16(3):255\u201382.","journal-title":"Target Oncol"},{"issue":"1","key":"2324_CR37","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1634\/theoncologist.2020-0697","volume":"26","author":"EN Risdon","year":"2021","unstructured":"Risdon EN, Chau CH, Price DK, et al. PARP inhibitors and prostate cancer: to infinity and beyond BRCA. Oncologist. 2021;26(1):e115\u201329.","journal-title":"Oncologist"},{"key":"2324_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.bcp.2019.03.028","volume":"167","author":"D Slade","year":"2019","unstructured":"Slade D. Mitotic functions of poly(ADP-ribose) polymerases. Biochem Pharmacol. 2019;167:33\u201343.","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"2324_CR39","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/cancers12071813","volume":"12","author":"M Engbrecht","year":"2020","unstructured":"Engbrecht M, Mangerich A. The nucleolus and PARP1 in cancer biology. Cancers (Basel). 2020;12(7):1813.","journal-title":"Cancers (Basel)"},{"issue":"21","key":"2324_CR40","doi-asserted-by":"publisher","first-page":"11441","DOI":"10.3390\/ijms222111441","volume":"22","author":"NV Maluchenko","year":"2021","unstructured":"Maluchenko NV, Feofanov AV, Studitsky VM. PARP-1-associated pathological processes: inhibition by natural polyphenols. Int J Mol Sci. 2021;22(21):11441.","journal-title":"Int J Mol Sci."},{"key":"2324_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2016.10.010","volume":"108","author":"A Dr\u00e9an","year":"2016","unstructured":"Dr\u00e9an A, Lord CJ, Ashworth A. PARP inhibitor combination therapy. Crit Rev Oncol Hematol. 2016;108:73\u201385.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"2324_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115434","volume":"28","author":"S Lin","year":"2020","unstructured":"Lin S, Zhang L, Zhang X, et al. Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities. Bioorg Med Chem. 2020;28(9): 115434.","journal-title":"Bioorg Med Chem"},{"issue":"15","key":"2324_CR43","doi-asserted-by":"publisher","first-page":"8412","DOI":"10.3390\/ijms23158412","volume":"23","author":"D Kim","year":"2022","unstructured":"Kim D, Nam HJ. PARP inhibitors: clinical limitations and recent attempts to overcome them. Int J Mol Sci. 2022;23(15):8412.","journal-title":"Int J Mol Sci."},{"key":"2324_CR44","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202201159","author":"E Eskandari","year":"2022","unstructured":"Eskandari E, Eaves CJ. Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis. J Cell Biol. 2022. https:\/\/doi.org\/10.1083\/jcb.202201159.","journal-title":"J Cell Biol."},{"issue":"6","key":"2324_CR45","doi-asserted-by":"publisher","first-page":"8203","DOI":"10.1002\/jcp.27628","volume":"234","author":"R Saraei","year":"2019","unstructured":"Saraei R, Marofi F, Naimi A, et al. Leukemia therapy by flavonoids: future and involved mechanisms. J Cell Physiol. 2019;234(6):8203\u201320.","journal-title":"J Cell Physiol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02324-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-024-02324-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02324-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T02:13:06Z","timestamp":1717035186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-024-02324-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["2324"],"URL":"https:\/\/doi.org\/10.1007\/s12032-024-02324-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3739210\/v1","asserted-by":"object"}]},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]},"assertion":[{"value":"11 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"113"}}